CIP
ALNY icon

Chartwell Investment Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Chartwell Investment Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,174
Closed -$1.17M – 415
2023
Q2 		$1.17M Sell
6,174
-4
-0.1% -$793 0.04% 342
2023
Q1 		$1.24M Buy
+6,178
New +$1.3M 0.05% 324

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Chartwell Investment Partners's ALNY Position: Q3 2023 in Review

Chartwell Investment Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2023, closing a stake of 6,174 shares — an estimated $1.17M sold.

Chartwell Investment Partners first reported a position in ALNY in Q1 2023 and held it in 2 quarters. The position peaked at $1.24M in Q1 2023. 452 funds tracked by Wall St. Rank hold ALNY as of Q3 2023.

  • Chartwell Investment Partners reported no remaining Alnylam Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Chartwell Investment Partners sold 6,174 Alnylam Pharmaceuticals shares in Q3 2023, an estimated $1.17M.
  • Chartwell Investment Partners first reported a position in Alnylam Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Chartwell Investment Partners's Alnylam Pharmaceuticals position peaked at $1.24M in Q1 2023.
  • 452 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2023.

Based on Chartwell Investment Partners's 13F filing for Q3 2023, filed 7 Nov 2023.